Linzhi Lu

机构：Fujian Medical University, Huawei Technologies (China), Mengchao Hepatobiliary Hospital

发表论文 32 篇 · 总被引 294 次 · h-index 10

代表论文

• Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study (2025 · Signal Transduction and Targeted Therapy · 被引 16)
• Risk factors in the development of gastric adenocarcinoma in the general population: A cross-sectional study of the Wuwei Cohort (2023 · Frontiers in Microbiology · 被引 16)
• A novel biotechnology for enhanced ciprofloxacin removal via bioaugmentation of Paraclostridium sp. (2022 · Bioresource Technology Reports · 被引 13)
• Association of single nucleotide polymorphisms (SNPs) with gastric cancer susceptibility and prognosis in population in Wuwei, Gansu, China (2022 · World Journal of Surgical Oncology · 被引 11)
• Cholecystectomy is associated with a higher risk of irritable bowel syndrome in the UK Biobank: a prospective cohort study (2023 · Frontiers in Pharmacology · 被引 10)
• Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer. (2025 · Journal of Clinical Oncology · 被引 9)